Healthcare Market Updates | BioTuesdays by Kilmer Lucas IR

Markets

WB starts P3 Health Partners at outperform

William Blair launched coverage of P3 Health Partners (NASDAQ:PIII) with an “outperform” rating, projecting 2022 revenue of 815.1-million; 2023 revenue of $1.2-billion; and 2024 revenue of $1.7-billion on adjusted...

January 4, 2022

Markets

BTIG starts Pear Therapeutics at buy; PT $12

BTIG initiated coverage of Pear Therapeutics (NASDAQ:PEAR) with a “buy” rating and $12 price target. The stock closed at $6.20 on Dec. 31. Pear is a leader in prescription digital therapeutics (PDTs), with three...

January 3, 2022

Markets

Cantor starts Vincerx Pharma at OW; PT $25

Cantor Fitzgerald initiated coverage of Vincerx Pharma (NASDAQ:VINC) with an “overweight” rating and $25 price target. The stock closed at $10.30 on Dec. 22. Vincerx is a clinical-stage oncology company that is on track...

December 23, 2021

Markets

HCW starts BioCardia at buy; PT $9

H.C Wainwright initiated coverage of BioCardia (NASDAQ:BCDA) with a “buy” rating and price target of $9. The stock closed at $1.71 on Dec. 17. BioCardia is a clinical-stage company focused on the development of cell...

December 20, 2021

Markets

Maxim starts Ayala at buy; PT $22

Maxim Group initiated coverage of Ayala Pharmaceuticals (NASDAQ:AYLA) with a “buy” rating and $22 price target. The stock closed at $9 on Dec. 17. Ayala is developing two gamma-secretase inhibitors – AL101 and...

December 20, 2021

Markets

HCW starts 89bio at buy; PT $46

H.C. Wainwright launched coverage of 89bio (NADAQ:ETNB) with a “buy” rating and price target of $46. The stock closed at $11.48 on Dec. 17. 89bio is a clinical-stage biopharmaceutical company focused on the development...

December 20, 2021

Markets

HCW starts Vor Biopharma at buy; PT $26

H.C. Wainwright initiated coverage of Vor Biopharma (NASDAQ:VOR) with a “buy” rating and $26 price target. The stock closed at $12.13 on Dec. 16. Vor is a clinical-stage cell therapy company focused on developing...

December 17, 2021

Markets

Cantor starts Cardiol at OW; PT $8

Cantor Fitzgerald launched coverage of Cardiol Therapeutics (NASDAQ:CRDL) with an “overweight” rating and price target of $8. The stock closed at $1.87 on Dec. 16. Cardiol is a clinical-stage, platform-enabled...

December 17, 2021

Markets

HCW starts Virios Therapeutics at buy; PT $12

H.C. Wainwright initiated coverage of Virios Therapeutics (NASDAQ:VIRI) with a “buy” rating and price target of $12. The stock closed at $4.58 on Dec. 14. Virios is a clinical-stage biotech company developing a novel...

December 15, 2021

Markets

Cowen starts Apollo Endosurgery at OP; PT $13

Cowen launched coverage of Apollo Endosurgery (NASDAQ:APEN) with an “outperform” rating and $13 price target. The stock closed at $7.64 on Dec. 14. APEN is focused on design, development and commercialization of novel...

December 15, 2021

Markets

HCW starts Gemini Therapeutics at buy; PT $20

H.C. Wainwright launched coverage of Gemini Therapeutics (NASDAQ:GMTX) with a “buy” rating and $20 price target. The stock closed at $2.43 on Dec. 14. Gemini is developing precision medicines for the treatment of...

December 15, 2021

Markets

WB cuts Generation Bio to market perform

William Blair downgraded Generation Bio (NASDAQ:GBIO) to “market perform,” citing variability in a non-human primate study in Factor VIII production for its hemophilia program. In mid-morning trading, the stock was...

December 14, 2021

Markets

SVB Leerink ups Zymeworks to OP from MP

SVB Leerink upgraded Zymeworks (NYSE:ZYME) to “outperform” from “market perform,” citing a sell-off in the stock that “makes us more constructive, despite some uncertainties.” The stock closed at $16.12 on Dec. 9...

December 10, 2021

Markets

HCW starts Delcath Systems at buy; PT $25

H.C. Wainwright initiated coverage of Delcath Systems (NASDAQ:DCTH) with a “buy” rating and 12-month price target of $25. The stock closed at $8.02 on Dec. 9. Delcath is a clinical-stage interventional oncology company...

December 10, 2021

Markets

Stifel starts Apollo Endosurgery at buy; PT $12

Stifel launched coverage of Apollo Endosurgery (NASDAQ:APEN) with a “buy” rating and $12 price target. The stock closed at $8.59 on Dec. 8. Apollo Endosurgery is a medical technology company focused on design...

December 9, 2021

Markets

Stifel cuts Bolt Biotherapeutics PT to $19 from $34

Stifel reduced its price target for Bolt Biotherapeutics (NASDAQ:BOLT) to $19 from $34, but maintained its “buy” rating, after the company presented interim clinical data from an ongoing Phase 1/2 study of BDC-1001, its...

December 6, 2021

Markets

AGP starts NeuroOne Medical at buy; PT $5.75

Alliance Global Partners launched coverage of NeuroOne Medical Technologies (NASDAQ:NMTC) with a “buy” rating and price target of $5.75. The stock closed at $2.09 on Dec. 2. NeuroOne’s flexible, thin-film...

December 3, 2021

Markets

Cantor cuts AcelRx PT to $4 from $9; maintains OW

Cantor Fitzgerald reduced its price target for AcelRx Pharmaceuticals (NASDAQ:ACX) to $4 from $9, but maintained its “overweight” rating, citing a revised ramp in Dsuvia sales, as well as recent acquisitions and an...

December 2, 2021

Markets

Brookline starts POINT Biopharma at buy; PT $23

Brookline Capital Markets initiated coverage of POINT Biopharma (NASDAQ:PNT) with a “buy” rating and $23 price target. The stock closed at $8.07 on Nov. 30. POINT is a late-stage clinical oncology company focused on...

December 1, 2021

Markets

Maxim starts Citius Pharma at buy; PT $4

Maxim Group launched coverage of Citius Pharmaceuticals (NASDAQ:CTXR) with a “buy” rating and $4 price target. The stock closed at $1.62 on Nov. 29. Citius is a late-stage company with two “de-risked” Phase 3 assets:...

November 30, 2021

Markets

SVB Leerink cuts Abeona Therapeutics to MP; PT to $1 from $5

SVB Leerink downgraded Abeona Therapeutics (NASDAQ:ABEO) to “market perform” from “outperform” and slashed its price target to $1 from $5 after stronger-than-expected data from competitor Krystal Biotech (NASDAQ:KRYS). ...

November 30, 2021

Markets

BTIG starts Freeline Therapeutics at buy; PT $10

BTIG launched coverage of Freeline Therapeutics (NASDAQ:FRLN) with a “buy” rating and price target of $10. The stock closed at $2.37 on Nov. 26. Freeline has built a next-generation gene therapy platform based on a...

November 29, 2021

Subscribe